11 reports

Top ## players hold majority of stake in the market ##.

  • Musculoskeletal Disorder
  • World
  • Market Size
  • Baxter International Inc.
  • Gilead Sciences, Inc.
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products

Encore presentation from the WCOG at ACG2017 ##.

  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.

Liraglutide is a glucagon-like peptide-## (GLP-##) receptor agonist.

  • Autoimmune Disease
  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## Pharmaceutical Product Development LLC ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## MallInckrodt Plc ## ## ## ## ## ## CSL Ltd ## ## ## ## ##

  • Medical Biotechnology
  • Musculoskeletal Disorder
  • World
  • Product Initiative
  • Novartis AG

As of April 2009, the drug candidate was in Phase II/ III stage of development for rasmussen s encephalitis.

  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Neurological Disorder
  • United States
  • Pfizer Inc.
  • 3. GDCT ID IS THE UNIQUE ID OF GLOBALDATA'S PHARMA INTELLIGENCE CENTER CLINICAL TRIAL DATABASE

In the study, ## patients were randomized ##:##:## to receive placebo, baricitinib ## mg or baricitinib ## mg.

  • Clinical Trial
  • Medical Biotechnology
  • Musculoskeletal Disorder
  • World
  • GlaxoSmithKline plc

The company provides treatment for myasthenia gravis, multiple sclerosis and autoimmune encephalitis and lupus.

  • Cell Therapy
  • Musculoskeletal Disorder
  • Neurological Disorder
  • Therapy
  • Anavex Life Sciences Corp.

The company provides treatment of myasthenia gravis, multiple sclerosis and autoimmune encephalitis and lupus.

  • Arthritis
  • Musculoskeletal Disorder
  • Neurological Disorder
  • Pathology
  • Anavex Life Sciences Corp.

AS OF APRIL 2009, THE DRUG CANDIDATE WAS IN PHASE II/ III STAGE OF DEVELOPMENT FOR RASMUSSEN' S ENCEPHALITIS.

  • Musculoskeletal Disorder
  • Neurological Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Musculoskeletal Disorder
  • Neurology
  • Therapy
  • World
  • Product Initiative

JAPANESE ENCEPHALITIS VIRUS, TICK-BORNE ENCEPHALITIS VIRUS, RABIES VIRUS, WEST NILE VIRUS).

  • Autoimmune Disease
  • Clinical Trial
  • Immunodiagnostics
  • Musculoskeletal Disorder
  • Phadia Group